Piramal PharmaNSE:PPLPHARMA +1.10%60 Current Ratio is 1.51 as of Mar. 2026, which is 16% above its 10-year median of 1.30. GuruFocus rates NSE:PPLPHARMA with a GF Score™ of 60/100 and a GF Value™ of ₹174.09 (Fairly Valued). The stock has 5 warning signs investors should review. Among 997 Drug Manufacturers companies, Piramal Pharma ranks worse than 65.4% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Piramal Pharma's current ratio for the quarter that ended in Mar. 2026 was 1.51.
Piramal Pharma has a current ratio of 1.51. It generally indicates good short-term financial strength.
The historical rank and industry rank for Piramal Pharma's Current Ratio or its related term are showing as below:
NSE:PPLPHARMA'
s Current Ratio Range Over the Past 10 Years
Min: 1.2 Med: 1.3 Max: 1.54
Current: 1.51
During the past 6 years, Piramal Pharma's highest Current Ratio was 1.54. The lowest was 1.20. And the median was 1.30.
NSE:PPLPHARMA's Current Ratio is ranked worse than 65.4% of 997
companies
in the Drug Manufacturers industry
Industry Median: 2
vs NSE:PPLPHARMA: 1.51
Piramal Pharma (NSE:PPLPHARMA) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Piramal Pharma Current Ratio Related Terms
Piramal Pharma Current Ratio Historical Data
* Premium members only.
The historical data trend for Piramal Pharma's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:PPLPHARMA vs ZTS, UTHR: Current Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Piramal Pharma's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Piramal Pharma Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Piramal Pharma's Current Ratio distribution charts can be found below:
* The bar in red indicates where Piramal Pharma's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Piramal Pharma (NSE:PPLPHARMA) has a Current Ratio of 1.51 as of Mar. 2026. This is 16% above median its historical median of 1.30. Over the past decade, Piramal Pharma's Current Ratio has ranged from 1.20 to 1.54. According to the industry distribution chart, Piramal Pharma ranks #652 out of 997 companies in the Drug Manufacturers industry, placing it in the top 65.4%.
Is Piramal Pharma's Current Ratio too high?
Piramal Pharma's current Current Ratio of 1.51 is 16% above median its 10-year median of 1.30. Over the past 10 years, this metric has ranged from a low of 1.20 to a high of 1.54. The Drug Manufacturers industry median Current Ratio is 2.00. Piramal Pharma's value of 1.51 is 24.5% below this industry median. Based on the distribution chart, Piramal Pharma ranks #652 out of 997 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Piramal Pharma has a GF Score™ of 60/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Piramal Pharma's Current Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Piramal Pharma ranks #652 out of 997 companies for Current Ratio. This places Piramal Pharma in the lower half of its industry. The industry median Current Ratio is 2.00. Piramal Pharma's value of 1.51 is 24.5% below this benchmark. Historically, Piramal Pharma's own Current Ratio has ranged from 1.20 to 1.54 over the past decade. While the company's 10-year median is 1.30 vs. the industry median of 2.00, Piramal Pharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 997 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Piramal Pharma's current Current Ratio of 1.51 is 24.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Piramal Pharma's current Current Ratio is 1.51, which is 16% above median its own 10-year median of 1.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Piramal Pharma stock overvalued right now?
Based on GuruFocus' analysis, Piramal Pharma (NSE:PPLPHARMA) is currently considered Fairly Valued. The stock's GF Value™ is ₹174.09, compared to a current price of ₹177.88 — trading 2.2% above its estimated fair value. The current Current Ratio is 1.51, which is 16% above median its 10-year median of 1.30 and 24.5% below the Drug Manufacturers industry median of 2.00. Piramal Pharma's overall GF Score™ is 60/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Piramal Pharma (NSE:PPLPHARMA), the current Current Ratio is 1.51 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Piramal Pharma (NSE:PPLPHARMA) Overvalued in 2026?
Based on GuruFocus' analysis, Piramal Pharma stock appears to be overvalued.
The current stock price of ₹177.88 is trading 2.2% above its estimated GF Value™ of ₹174.09.
GuruFocus considers Piramal Pharma to be Fairly Valued.
Key valuation signals for NSE:PPLPHARMA:
Current Ratio: 1.51 (16% above median its 10-year median of 1.30)
GF Value™: ₹174.09 vs. price of ₹177.88 (2.2% above fair value)
Industry Position: 24.5% below the Drug Manufacturers median (#652 of 997)
No single metric tells the full story. See the NSE:PPLPHARMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Piramal Pharma Ltd is a pharmaceutical company, providing end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and international distribution network. It operates under three business verticals; an integrated contract development and manufacturing (CDMO) business providing Active pharmaceutical ingredients (APIs), Finished dosage forms (FDFs), biologics, and vaccines among other products; the other two business verticals include a complex hospital generics business, and an India consumer healthcare business, selling over-the-counter products in India. Geographically, the company generates maximum revenue from North America and the rest from Europe, India, Japan, and other markets.
60GF Score
Get the complete analysis for NSE:PPLPHARMA
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:PPLPHARMA has been successfully added to your 
